The news out overnight from Berlin, Germany is that SCENION has partnered with Anteo Diagnostics (ASX:ADO) to develop consumables for better functionality and longer shelf life of protein microarrays.
From the above announcement :
"The project will combine the advantages of the Mix&Go technology with the capability of SCIENION’s precision spotting sciFLEXARRAYER technology, with the objective of delivering more accurate results and better, longer-lasting and more cost effective diagnostics. The first targeted products of the Anteo and SCIENION collaboration will be activated glass and polymer slides.
Josh Soldo, VP Scientific Affairs at Anteo explains: “With SCIENION, we have found a partner with deep expertise in surface functionalization and protein spotting, and one with excellent products. As a result of our partnership, scientists will soon have the tools that they need to overcome the present limitations of protein arrays, and increase the performance of their arrays, while reducing the sample size needed to get results. In brief, we expect the partnership to yield more effective tests with better specificity.”
Holger Eickhoff, CEO of SCIENION, says: "As a very customer focused company, we always seek to expand the portfolio of solutions we can propose to help implement the various platform technologies that our customers bring to us. Anteo’s new coating technology will enable us to provide an even higher level of customer application support via unprecedented combinations of materials, surfaces and deposition technology. The perfect pairing of the right surface with the right dispensing is key to a successful application where a biological molecule is deposited to become attached to a surface. The expertise of both companies is very complementary, and together we will exploit the resulting synergies.”
Both SCIENION and Anteo will be in attendance at the AACC Annual Meeting and Clinical Lab Expo in Atlanta, GA, USA from July 26-30, 2015; . Find us here: SCIENION at booth 4411, Anteo Technologies at booth 4564"
MY THOUGHTS ON THE ABOVE ANNOUNCEMENT
This SCENION news is very solid news and potentially company making for a few important reasons :
Firstly lets slightly sidetrack for a moment - As readers and holders of Anteo know for some time Anteo have been working with a Global Healthcare company known for confidentiality reasons as "POC1" - Although not formally named it is fairly clear that this is Philips Healthcare.
Philips are working on developing a Handheld POC device with the first test on the device targeting Myocardial Infarction by detecting a protein called Troponin which is released into the bloodstream following a cardiac injury/event when the heart muscle is damaged Troponin is released and is therefore a way of diagnosing if a patient has had myocardial infarction (MI). Testing for this has to date been done in laboratories which is time consuming and leaves the patient in the Emergency room for longer. The planned development by Philips is for a truly handheld portable device that can deliver lab quality tests to a portable point of care device. Philips planned device is called MINICARE.
Ok so that is a little background on Philips and the Minicare device they are developing but you may be wondering why is this relevant to SCENION.
So back at the end of 2014 "POC1" sent a $250k odd machine to Anteo Diagnostic labs in Brisbane, Australia to help optimise the sensor surface for the Minicare Device.
The machine "POC1" sent was a ....... Drumroll please
Click below link :
The below is from Anteo's Quarterly report dated 30th January 2015 :
"POC 1 - our scientists have continued to seek further improvements to the particles we delivered to our partner in May 2014. Two different products were developed and assessed in our laboratories to be superior to our May offering. Extensive testing of these particles in their laboratories has confirmed our belief and prompted our partner to request a technology transfer The second phase of our collaboration program with PoC1 revolves around the ability of Mix&Go to improve the performance of their sensor surfaces and, in all likelihood, the entire device. The Scienion instrument has now been installed in our laboratory and our scientists have been trained in its use. PoC1 has now requested that we focus our ongoing attention on this aspect of the device."
Still with me - ok let's move along - Now lets have a look at the link below which is the clinical project being undertaken for the MINICARE PROJECT :
From the Lab2Go website :
About the consortium
"The goal of the Lab2Go project is to bring a (handheld) Point-of-Care test-device to the next level of maturity by demonstrating it in real user environments. The aim is to have a solution available at the end of the project which meets the targeted system specifications and which is accepted by the intended users and is ready for clinical validation."
So to finish - If the CEO of SCENION says this :
"Holger Eickhoff, CEO of SCIENION, says: "As a very customer focused company, we always seek to expand the portfolio of solutions we can propose to help implement the various platform technologies that our customers bring to us. Anteo’s new coating technology will enable us to provide an even higher level of customer application support via unprecedented combinations of materials, surfaces and deposition technology. The perfect pairing of the right surface with the right dispensing is key to a successful application where a biological molecule is deposited to become attached to a surface. The expertise of both companies is very complementary, and together we will exploit the resulting synergies.”
And we know that Philips use the SCENION machine for the MINICARE project than - well I will let you join the dots.
This isn't so much about SCENION as a company on their own but who and what they are working on.
Also the timing for this to be released just before the AACC 2015 global meeting next week couldn't be any better.
DISCLOSURE : THE AUTHOR HOLDS SHARES IN THIS COMPANY. THIS RESEARCH IS NOT A RECOMMENDATION TO BUY OR SELL SHARES IN THIS COMPANY. THE AUTHOR MAY AT ANY TIME BUY OR SELL SHARES WITHOUT NOTICE. PLEASE DO YOUR OWN RESEARCH